Titan and Lupin seem poised for solid gains among Rakesh Jhunjhunwala's portfolio, while shares of Lupin, Star Health and Jubilant Pharmova can be avoided for now.
![Avatar](https://cdn.statically.io/img/i.pinimg.com/140x140_RS/66/86/44/6686445668b6ae618052e75ad04653e0.jpg)
Anshuman Behera